Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Annexon, Inc.

Market Cap 772M 667M 614M 575M 1.08B 73.35B 1.09B 7.25B 2.83B 35.7B 2.9B 2.83B 124B P/E Ratio 2026 *
-5.02x
P/E Ratio 2027 * -6.01x
Enterprise Value 677M 585M 539M 505M 946M 64.37B 960M 6.36B 2.48B 31.33B 2.54B 2.49B 108B EV / Sales 2026 *
-
EV / Sales 2027 * 11.7x
Free-Float
93.59%
Yield 2026 *
-
Yield 2027 * -
1 day+0.21%
1 week-10.96%
Current month-13.10%
1 month-13.58%
3 months-16.78%
6 months-5.23%
Current year-6.18%
1 week 4.59
Extreme 4.59
5.46
1 month 4.59
Extreme 4.59
5.92
Current year 4.54
Extreme 4.545
7.18
1 year 1.85
Extreme 1.85
7.18
3 years 1.28
Extreme 1.285
8.4
5 years 1.28
Extreme 1.285
24.85
10 years 1.28
Extreme 1.285
38.01
Manager TitleAgeSince
Chief Executive Officer 58 2014-11-30
Director of Finance/CFO 53 2019-05-31
Chief Tech/Sci/R&D Officer 68 2023-07-26
Director TitleAgeSince
Director/Board Member 58 2014-11-30
Director/Board Member 65 2014-11-30
Director/Board Member 67 2021-02-04
Date Insider Type Main position Quantity % Market Cap.
05-27
Alerce Investment Management LP
BuyCompany 613,497 0.3775%
05-10Buy

Director

8,000 0.0049%
04-09Buy

Director

8,000 0.0055%
Change 5-day change 1-year change 3-year change Capi.($)
+0.21%-10.96%+89.16%+51.94% 772M
+1.03%+2.30%+55.91%+114.22% 56.42B
+2.72%+3.26%+46.05%+44.91% 44.54B
+1.12%+2.79%-15.04%-21.68% 22.9B
+1.17%+3.85%-0.89%+403.86% 21.21B
+3.81%-5.07%+11.00%-30.62% 16.4B
+0.15%+2.24%+9.32%-39.30% 15.4B
-0.69%+0.82%+27.75%+176.72% 13.35B
+5.27%+5.54%+19.65% - 12.36B
+1.61%+1.28%+95.75%+205.26% 11.15B
Average +1.64%+0.78%+33.87%+100.59% 21.45B
Weighted average by Cap. +1.72%+2.32%+32.24%+99.41%

Financials

2026 *2027 *
Net sales - 41M 35.41M 32.63M 30.54M 57.24M 3.9B 58.13M 385M 150M 1.9B 154M 151M 6.57B
Net income -188M -163M -150M -140M -263M -17.91B -267M -1.77B -690M -8.72B -707M -692M -30.18B -176M -152M -140M -131M -246M -16.76B -250M -1.66B -646M -8.16B -662M -648M -28.25B
Net Debt -94.47M -81.6M -75.19M -70.38M -132M -8.98B -134M -888M -346M -4.37B -355M -347M -15.13B -292M -252M -232M -217M -408M -27.74B -414M -2.74B -1.07B -13.5B -1.1B -1.07B -46.76B
Logo Annexon, Inc.
Annexon, Inc. is a clinical-stage biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. It identifies and characterizes the role of the classical complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology, using its proprietary platform. Its lead candidate, ANX005, an investigational, full-length monoclonal antibody (mAb), is formulated for intravenous administration as the potential first targeted treatment for patients with Guillain-Barre Syndrome (GBS). It is advancing ANX1502, a novel small-molecule inhibitor of classical complement designed for oral administration in a range of chronic autoimmune diseases. It is also advancing ANX007, designed to block C1q locally in the eye, to provide complete protection against excess classical complement activity and the loss of photoreceptor neurons.
Employees
93
Date Price Change Volume
26-06-12 4.710 $ +0.21% 3,196,199
26-06-11 4.700 $ -0.42% 1,673,915
26-06-10 4.720 $ -9.23% 2,627,039
26-06-09 5.200 $ +1.56% 3,194,947
26-06-08 5.120 $ -3.21% 3,315,505
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
4.710USD
Average target price
13.12USD
Spread / Average Target
+178.66%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ANNX Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!